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Abstract Surgery remains the only option to cure pan-
creatic cancer. Although the use of laparoscopy in oncol-
ogy is rapidly growing worldwide, its efficacy in pancreatic
surgery remains controversial. A number of studies have
compared outcomes of minimally invasive and open pan-
creatic resections. However, they are mostly non-random-
ized trials including relatively small groups of patients. In
addition, most of these studies were conducted in high-
volume pancreatic centres. It seems that despite longer
operative time, laparoscopy may be beneficial in terms of
morbidity, blood loss and hospital stay. Thus far, very little
is known about the long-term outcomes of laparoscopic
surgery for pancreatic cancer. Our aim was to review
current evidence for the use of minimally invasive tech-
niques in patients with pancreatic malignancy.
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Introduction
Pancreatic cancer is one of the most aggressive malig-
nancies associated with extremely poor 5-year survival
rate (*6–7%) [1]. Since the tumour remains asymp-
tomatic in the early stage, only 15% of patients have
resectable disease at diagnosis [2]. In the remaining
cases, local infiltration, invasion of surrounding vessels
and the presence of early distant metastases are con-
sidered the major causes precluding radical surgical
treatment. It has been calculated that in 2016 the rate of
pancreatic cancer in European population was around
8/100,000 in men and 5.7/100,000 in women [3]. In a
report published in 2016 by Ferlay et al., authors sug-
gest there will be more deaths annually from pancreatic
cancer in the European Union countries than deaths
from breast cancer. With predicted 91,500 deaths from
pancreatic cancer, the disease may become the third
most important cause of cancer death in the EU, after
lung and colorectal cancers, within the span of a few
years [4]. Despite aggressive treatment combining sur-
gery with systemic chemotherapy, the median survival
in patients undergoing radical resection estimated for
25–28 months is still unsatisfactory [5]. It also drops
below 12 months in unresectable patients treated with
palliative chemotherapy/radiotherapy only [1].
Surgery remains the only option to cure pancreatic
malignancies. Since first reports by Walther Kausch in
1912 and Allen Whipple in 1935, the operative technique
and perioperative care have been gradually improved.
Post-operative mortality has decreased from 30% in the
early years to 3–5%, as shown in the most recent analyses
[6–8]. Nevertheless, pancreatic cancer surgery is still
associated with relatively high morbidity of approximately
40% [9].
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Historically, the first laparoscopic pancreatoduodenectomy
(LPD) was performed in 1994 by Michel Gagner, and since
then, one of the most complex and demanding abdominal
procedures entered the world of minimally invasive sur-
gery [10]. Interestingly, the same author published three
years later a series of 10 cases in which the mean operative
time was 8.5 h and the conversion rate was 40% [11]. He
concluded that although it was feasible, the advantages of a
complete laparoscopic Whipple were questionable. There
are, however, several well-known benefits of laparoscopic
approach, which include: faster recovery, reduced inflam-
matory response, reduced intraoperative blood loss, less
post-operative pain, decreased morbidity and better cos-
metic effect. For these reasons, the use of laparoscopy is
rapidly growing worldwide. It has been documented that
laparoscopic surgery is feasible and safe in other disci-
plines of oncologic surgery. More than two decades later,
minimally invasive pancreatoduodenectomy is still a sub-
ject of debate. One can argue whether a 5- to 8-h-long
surgical procedure, involving removal of a part of the
pancreas, distal stomach, entire duodenum and the gall-
bladder, can really be called a ‘minimally invasive’ pro-
cedure? On the one hand, MIPD does not require long
incision, and for this reason, it can indeed be called ‘less
invasive’. On the other hand, surgical trauma related to the
extent of dissection, regardless of the approach, significant
alterations in gastrointestinal anatomy, relatively high
morbidity and long hospital stay definitely speak against
the minimally invasiveness of this procedure.
A number of systematic reviews compared outcomes of
minimally invasive (laparoscopic, hand-assisted or robotic)
and open pancreatoduodenectomy. However, many of them
include studies comprising pure MIPD and hybrid proce-
dures, where the dissection is performed minimally inva-
sively, but the anastomoses are created manually via
minilaparotomy [12–14]. The most recently published
meta-analysis included 12 non-randomized studies (only 2
of them were prospective) with a total of 2186 patients
(705 underwent MIPD and 1481 underwent open proce-
dure) [15]. Only studies involving pure MIPD (meaning
both resection and anastomoses were performed in a min-
imally invasive fashion) were included. In eight studies,
patients underwent robotic pancreatoduodenectomy (RPD),
while four papers analysed laparoscopic cases. The oper-
ative time was significantly longer in MIPD group (464 vs.
388 min), whereas blood loss and length of stay decreased.
Although there were differences in the rate of delayed
gastric emptying in the laparoscopic subgroup, it was not
different in robotic cases. Pancreatic fistula rate, as well as
the overall morbidity, did not vary between groups. In
addition, authors analysed oncologic outcomes in patients
with pancreatic ductal adenocarcinoma. Resection margin
status was extracted from six studies, and a subsequent
meta-analysis revealed no significant differences between
the groups. R1 resection was present in 62/223 (27.80%) in
MIPD cases versus 200/727 (27.51%) in open approach
group. Similarly, the number of harvested lymph nodes was
not different in laparoscopic nor robotic group in com-
parison with open approach. The review addressed poten-
tial risks of bias, one of them being different size of
removed tumours (smaller in MIPD group). In addition, all
studies contained patients from high-volume centres, which
presented slightly different operative technique in each of
them—this might have influenced the final outcomes. The
authors concluded that minimally invasive pancreatic head
cancer surgery is not ready for general application and
should be performed in specialized high-volume pancreatic
centres with extensive expertise in minimally invasive
surgery.
The data on long-term survival in MIPD are very sparse.
Five-year survival in pancreatic cancer, reported by Pala-
nivelu et al., was 32%. However, the majority of included
patients had early-stage cancers [16]. Because there are
only two comparative studies that show no differences in
survival in MIPD versus open surgery for pancreatic head
cancer, the results of remaining studies are awaited
[17, 18]. Some authors suggested that to improve
resectability, the so-called artery first approach (where
superior mesenteric artery is dissected in the early phase of
resection, before any irreversible step is taken) may be
used [19, 20]. In theory, it allows early determination of
resectability and decreases R1 resection rate. There are in
fact six different approaches to early isolation of the artery,
and the choice between them depends on the tumour
location and the extent of infiltration [21]. This approach
has been shown feasible in laparoscopic surgery as well,
however, only in case studies; therefore, firm conclusions
about its benefits cannot be drawn [22, 23].
It has been shown that involvement of major veins
(superior mesenteric or portal vein) is no longer a con-
traindication for surgical resection in locally advanced
pancreatic cancer. Patients undergoing en bloc resection
with the involved vein may have similar long-term onco-
logic survival as compared to those without vascular
involvement [24–26]. In borderline tumours, addition of
neoadjuvant treatment may be beneficial in both
resectability and survival [27]. There are very few pan-
creatic centres that report minimally invasive vascular
resections in pancreatic head surgery [28–30]. Laparo-
scopic approach is feasible in the hands of an extremely
experienced surgeon and may be associated with reduced
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blood loss and shortened length of stay. Perhaps wider
implementation of robotic surgery (wider range of motion,
greater accuracy and better ergonomics) will facilitate
vascular reconstruction during MIPD. However, it seems
that so far open approach will remain the mainstay when it
comes to vascular involvement.
It is clear that the outcomes of laparoscopic surgery are
related to skill and experience of the surgeon carrying out
the procedure as well as the institution and its annual
volume.
Previous studies have estimated that the learning curve
is at least 50 cases for laparoscopic approach and 33 (up to
80 in one report) for robotic access [31, 32]. MIPD is a
demanding procedure, involving meticulous dissection
around important vessels, difficult anatomy with a rela-
tively high rate of anatomical abnormalities, long operating
time and difficult anastomoses. Currently, there is no
standardized surgical training for those who are willing to
make their first attempts with MIPD; therefore, full
expertise in laparoscopic surgery and open pancreatoduo-
denectomy is needed. In addition, when analysing out-
comes of MIPD, the information on the learning curve is
usually not provided, which may bias the results. It has
been established that hospital volume correlates with
perioperative mortality and it is particularly noticeable in
pancreatic surgery [33, 34]. In case of MIPD, Adam et al.
[35] estimated that the annual institutional volume of 22
procedures is enough to obtain acceptable outcomes. This,
in fact, means that the institutional volume has to be
higher, taking into consideration that not every tumour is
suitable for MIPD, especially at the beginning of the
learning curve.
Laparoscopic distal (left) pancreatectomy (LDP)
Operations of the body and the tail of the pancreas and
pancreatic head surgery are different for many reasons.
Firstly, the majority of LDP pancreatectomies are per-
formed for benign tumours, and in these cases, the proce-
dure itself is less extensive, especially in spleen-preserving
cases. Because there are no gastrointestinal anastomoses—
including pancreatic anastomosis—it literally eliminates
one of the major causes of morbidity. On the other hand,
cancers of the body and tail of the pancreas are usually
diagnosed in a more advanced stage due to asymptomatic
course. Malignant cases require appropriate lym-
phadenectomy (in Gerota’s fascia plane) and splenectomy.
This can also be a potential cause of morbidity.
First reports of laparoscopic distal pancreatectomy were
made by Sir Alfred Cushieri in 1994 for chronic pancre-
atitis [36]. Unlike pancreatic head resection, distal pan-
createctomy has been adopted more widely. It is now a
generally accepted procedure for all benign lesions [37].
According to the recent survey,  of hepatobiliary sur-
geons have had experience in laparoscopic distal pancrea-
tectomy. Having said that, the median proportion of
laparoscopic and open approach per surgeon was still only
30% [38]. Although the enthusiasm for LDP seems to be
higher than for the MIPD and is steadily increasing, the
evidence for the use of minimally invasive approach in
cancer is still very limited. Therefore, surgeons are rather
reluctant to adopt LPD in cancer cases. Malignant diag-
nosis is a contraindication to laparoscopic surgery by every
third surgeon, and two-thirds of them would not use LPD in
multi-visceral involvement [38].
There have been several meta-analyses so far; however,
due to the retrospective nature of included studies and high
proportion of benign lesions, all of them are prone to
selection bias; therefore, firm conclusions on oncologic
benefits cannot be drawn [39]. Looking into results, several
potential benefits of minimally invasive access were
observed: reduced blood loss, lower morbidity in most of
previous meta-analyses (OR 0.71–0.92) and shortened
length of hospital stay (by 2.7 up to 12.3 days). Based on
the available literature, LPD can be certainly offered to
patients with benign lesions and, in the hands of experi-
enced surgeon, may prove to be beneficial. But what about
pancreatic cancer cases? In April 2016, a Cochrane review
was published by Riviere et al. [40]. It finally included 11
studies (1506 participants: 353 undergoing laparoscopic
distal pancreatectomy and 1153 undergoing open distal
pancreatectomy for cancer). All of them were cohort or
case–control studies with a high risk of bias. The authors
concluded that oncologic results were very imprecise and
therefore cannot be translated into firm conclusions about
feasibility and safety of minimally invasive distal pancre-
atectomy for cancer. Looking at the most recent systematic
review on LDP in pancreatic cancer, only one study
reported higher lymph node yield in minimally invasive
group, whereas in the remaining nine studies, there were no
differences [41]. Patients undergoing laparoscopic proce-
dure were more likely to receive adjuvant chemotherapy
earlier (70 vs. 96 days). However, this has not transferred
into differences in survival (26 vs. 25 months). It is
somehow surprising that more than 20 years after intro-
duction of laparoscopic distal pancreatectomy, with rela-
tively high adoption of this procedure, no randomized
controlled trial has been conducted until today. It is even
more surprising that in every review on laparoscopic pan-
creatic resection, the need for a randomized controlled trial
is clearly stated and, so far, we encountered only two
ongoing projects—the Dutch LEOPARD-1 multicentre
randomized controlled trial (http://www.trialregister.nl/
trialreg/admin/rctview.asp?TC=5188, estimated comple-
tion date 10 April 2017) and the Swedish LAPOP single-
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centre randomized controlled trial (http://www.isrctn.com/
ISRCTN26912858 estimated completion date in 2020).
In all but one previous meta-analyses (by Nigri et al.),
the rate of post-operative pancreatic fistula was comparable
regardless of the used technique [39, 42]. Even though a
Cochrane review by Probst et al. showed no differences
between stapler and scalpel resection, followed by hand-
sewn closure of the pancreatic remnant for distal pancre-
atectomy, for obvious reasons practically all LPDs are
performed with the use of linear stapler and the pancreatic
fistula rate remains high (30–40%) [43].
Similarly to open surgery, in line with EAES guidelines,
spleen-preserving LPD can be considered in patients with
benign tumours [37]. Although spleen preservation is
associated with longer operative time, it may lead to
reduced morbidity (including pancreatic fistula) and shorter
LOS [44]. However, the data are contradictory [45, 46]. All
these studies comprise relatively small non-randomized
cohorts of patients with smaller, benign tumours.
Finally, the introduction of laparoscopy into surgery of
the body and tail of the pancreas may have positive impact
on post-operative quality of life [47, 48]. At the same
time, the direct costs of the surgical procedure are higher
comparing to open distal pancreatectomy; however, they
can be probably balanced with reduced post-operative
costs [37].
Conclusions
In conclusion, based on the review of available literature,
minimally invasive pancreatic surgery for cancer is feasi-
ble. In the hands of an experienced surgeon, MIPD can be
considered a safe alternative to open approach for benign
tumours. However, the evidence on long-term outcomes of
minimally invasive access in pancreatic head ductal car-
cinoma is still sparse. The situation is similar in the case of
LPD—it may very well serve as an option to treat tumours
located in the body and tail of the organ, but more trials are
required to show its oncologic benefits in long-term period.
Although the introduction of minimal access may be
helpful in terms of length of stay and blood loss, MIPD is
still an extensive surgical trauma; thus, other ways to
diminish it are still desired. For instance, the introduction
of modern perioperative care programmes based on ERAS
(enhanced recovery after surgery) principles has been
shown to accelerate patients’ recovery, which enables
earlier discharge, including open cases [49, 50]. In addi-
tion, as demonstrated in other surgical disciplines, thanks
to high compliance with ERAS protocol, it is possible to
eliminate traditional risk factors for complications and
prolonged length of stay [51, 52]. Perhaps, it is also the
pathway upon which novel pancreatic surgery is set to
venture, along with minimizing the length of incision, with
the sole goal of further improving outcomes.
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Navarro S. Curative laparoscopic resection for pancreatic neo-
plasms: a critical analysis from a single institution. J Gastrointest
Surg. 2007;11:1607–22.
46. Mekeel KL, Moss AA, Reddy KS, Mulligan DC, Harold KL.
Laparoscopic distal pancreatectomy: does splenic preservation
affect outcomes? Surg Laparosc Endosc Percutan Tech.
2011;21:362–5.
47. Ricci C, Casadei R, Taffurelli G, Bogoni S, D’Ambra M, Ingaldi
C, et al. Laparoscopic distal pancreatectomy in benign or pre-
malignant pancreatic lesions: is it really more cost-effective than
open approach? J Gastrointest Surg. 2015;19:1415–24.
48. Braga M, Pecorelli N, Ferrari D, Balzano G, Zuliani W, Castoldi
R. Results of 100 consecutive laparoscopic distal pancreatec-
tomies: postoperative outcome, cost-benefit analysis, and quality
of life assessment. Surg Endosc. 2015;29:1871–8.
49. Coolsen MME, van Dam RM, van der Wilt AA, Slim K, Lassen
K, Dejong CHC. Systematic review and meta-analysis of
Med Oncol (2017) 34:125 Page 5 of 6 125
123
enhanced recovery after pancreatic surgery with particular
emphasis on pancreaticoduodenectomies. World J Surg.
2013;37:1909–18.
50. Kagedan DJ, Ahmed M, Devitt KS, Wei AC. Enhanced recovery
after pancreatic surgery: a systematic review of the evidence.
HPB (Oxford). 2015;17:11–6.
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